Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Purchases of Investments

Cash used to buy marketable securities and other investments.

Protalix BioTherapeutics, Inc.AMEX: PLX

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments outflow grows to $0

Q1 FY2026 purchases of investments was $0, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was $0. Over 3 fiscal years it compounded at -64.7% a year.

Context

  • Purchases of investments amounted to 1.3% of revenue in FY2025, down 26.8 pp from a year earlier.
  • Purchases of investments grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
-$702K-95.3% YoY
LTMMar 2026
$0— YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-95.3%——
3-year CAGR-64.7%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(702K) USD
Year-over-year change
+95.3%

Purchases of Investments vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's LTM Mar 2026 purchases of investments of $0 is the 3rd largest of the 4 companies compared; the peer median is $103.32M.
  • Purchases of investments amounts to 0.0% of revenue for PLX, versus a peer median of 37.7%.
PLX Competitors Peer median
Purchases of Investments for PLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$317M -18.0%-32.9%47.4%
PHARPharming Group N.V.LTM Mar 2026$103.32M -45.5%—28.0%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$0 —-64.7%0.0%
PLYXPolaryx Therapeutics, Inc. Common StockFY2025$0 ———
Peer median (excluding PLX) $103.32M-31.8%-32.9%37.7%

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.58M)(14.93M)8.31M2.93M(6.6M)
Depreciation & Amortization1.12M1.09M1.19M1.3M1.47M
Deferred Income Tax00(3.09M)236K340K
Stock-Based Compensation2.38M2.09M3.45M3.25M2.3M
Change in Working Capital9.9M(12.02M)(10.54M)811K(10.1M)
Accounts Receivables(1.03M)(1.19M)(428K)2.32M(5.89M)
Inventory(4.87M)1.15M(2.24M)(2.2M)(4.49M)
Accounts Payables00000
Other Working Capital15.81M(11.97M)(7.87M)692K277K
Other Non-Cash Items3.9M(1.23M)(638K)138K608K
Operating Cash Flow(10.29M)(25M)(1.32M)8.67M(11.99M)
Capital Expenditures(1.46M)(628K)(1.15M)(1.28M)(1.64M)
Acquisitions (Net)00000
Purchases of Investments(37.84M)(16M)(20.42M)(15M)(702K)
Sales of Investments57.84M11M5M20.42M0
Other Investing Activities380K593K(142K)83K(26K)
Investing Cash Flow18.92M(5.04M)(16.71M)4.22M(2.37M)
Debt Repayment(34.12M)00(20.42M)0
Common Stock Issued46.2M8.24M23.95M3.63M9.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities02K712K00
Financing Cash Flow12.08M8.24M24.67M(16.79M)9.33M
Effect of Forex Changes6K(77K)(114K)25K655K
Net Change in Cash20.72M(21.87M)6.52M(3.87M)(4.38M)
Free Cash Flow(11.74M)(25.63M)(2.47M)7.39M(13.63M)

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.